Trial reportDiabetes1995
Levels of lipoprotein(a), apolipoprotein B, and lipoprotein cholesterol distribution in IDDM. Results from follow-up in the Diabetes Control and Complications Trial.
Trial report in Diabetes, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 66 citations in OpenAlex.
- Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study.Diabetes care · 2019Trial
- Lifestyle and metformin treatment favorably influence lipoprotein subfraction distribution in the Diabetes Prevention Program.The Journal of clinical endocrinology and metabolism · 2013Trial
- Lipid and inflammatory cardiovascular risk worsens over 3 years in youth with type 2 diabetes: the TODAY clinical trial.Diabetes care · 2013 · on this mapTrial
- Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study.Diabetic medicine : a journal of the British Diabetic Association · 2013Trial
- Trial
- Increased small dense LDL and intermediate-density lipoprotein with albuminuria in type 1 diabetes.Diabetes care · 1999Trial
- Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial.JAMA · 1998 · on this mapTrial
- [Arterial mediacalcinosis in patients with diabetes mellitus: etiopathogenetic and histopathological aspects].Problemy endokrinologii · 2024Review
- The Roles of Fatty Acids and Apolipoproteins in the Kidneys.Metabolites · 2022Review
- Cardiovascular Risk in Type 1 Diabetes Mellitus.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2019Review
- The effects of basal insulin peglispro vs. insulin glargine on lipoprotein particles by NMR and liver fat content by MRI in patients with diabetes.Cardiovascular diabetology · 2017Article
- Lipoprotein (a): impact by ethnicity and environmental and medical conditions.Journal of lipid research · 2016Review
- Associations between intensive diabetes therapy and NMR-determined lipoprotein subclass profiles in type 1 diabetes.Journal of lipid research · 2016Article
- Intraabdominal fat, insulin sensitivity, and cardiovascular risk factors in postpartum women with a history of preeclampsia.American journal of obstetrics and gynecology · 2015Article
- Anti-atherogenic potential of jujube, saffron and barberry: anti-diabetic and antioxidant actions.EXCLI journal · 2015Article
- Lipoprotein(a) and cardiovascular disease in diabetic patients.Clinical lipidology · 2012Article
- Association of glycaemia with lipids in adults with type 1 diabetes: modification by dyslipidaemia medication.Diabetologia · 2010Article
- Cardiovascular risk factors among youth with and without type 2 diabetes: differences and possible mechanisms.Diabetes care · 2009Article
- Prevalence and determinants of elevated apolipoprotein B and dense low-density lipoprotein in youths with type 1 and type 2 diabetes.The Journal of clinical endocrinology and metabolism · 2008Article
- LDL composition in E2/2 subjects and LDL distribution by Apo E genotype in type 1 diabetes.Atherosclerosis · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Levels of lipoprotein(a) [Lp(a)], apolipoprotein (apo) B, and lipoprotein cholesterol distribution using density-gradient ultracentrifugation were measured as part of a cross-sectional study at the final follow-up examination (mean 6.2 years) in the Diabetes Control and Complications Trial. Compared with the subjects in the conventionally treated group (n = 680), those subjects receiving intensive diabetes therapy (n = 667) had a lower level of Lp(a) (Caucasian subjects only, median 10.7 vs 12.5 mg/dl, respectively; P = 0.03), lower apo B (mean 83 vs. 86 mg/dl, respectively; P = 0.01), and a more favorable distribution of cholesterol in the lipoprotein fractions as measured by density-gradient ultracentrifugation with less cholesterol in the very-low-density lipoprotein and the dense low-density lipoprotein fractions and greater cholesterol content of the more buoyant low-density lipoprotein. Compared with a nondiabetic Caucasian control group (n = 2,158), Lp(a) levels were not different in the intensive treatment group (median 9.6 vs. 10.7 mg/dl, respectively; NS) and higher in the conventional treatment group (9.6 vs. 12.5 mg/dl, respectively; P < 0.01). No effect of renal dysfunction as measured by increasing albuminuria or reduced creatinine clearance on Lp(a) levels could be demonstrated in the diabetic subjects. Prospective follow-up of these subjects will determine whether these favorable lipoprotein differences in the intensive treatment group persist and whether they influence the onset of atherosclerosis in insulin-dependent diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.